Your shopping cart is empty

You are about to log out of

Would you like to place your order before you log out?

Log Out Continue Shopping

Prescribing Information

Before administering Menactra vaccine, please see full Prescribing Information.

Reimbursement Information


Meningococcal (Groups A,C,Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

Log in to order

About Menactra Vaccine

2 Male teens wearing tiny football and hockey uniform holding equipment. Menactra vaccine information. Product box and vial.
RESERVE MENACTRA VACCINE TODAY Important Safety Information for Menactra Vaccine

Menactra vaccine is contraindicated in persons who have had a severe allergic reaction (eg, anaphylaxis) after a previous dose of a meningococcal capsular polysaccharide-, diphtheria toxoid-, or CRM197- containing vaccine, or to any component of the vaccine.

Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS following receipt of Menactra vaccine. GBS has been reported in temporal relationship following administration of Menactra vaccine. The decision to give Menactra vaccine should be based on careful consideration of the potential benefits and risks.

Syncope (fainting) can occur in association with administration of injectable vaccines, including Menactra vaccine. Procedures should be in place to prevent falling injury and manage syncopal reactions.

The most common local and systemic adverse reactions to Menactra vaccine include pain, redness, and swelling at the injection site and appetite loss (all age groups); induration at the injection site and diarrhea (all age groups except infants); irritability and drowsiness (infants and children); abnormal crying, vomiting, and fever (infants); headache, fatigue, malaise, and arthralgia (adolescents and adults). Other adverse reactions may occur. Vaccination with Menactra vaccine may not protect all individuals.


Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menactra vaccine is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent N meningitidis serogroup B disease.

Before administration, please see the full Prescribing Information for Menactra vaccine.

References: 1. Menactra vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc. 2. Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2013;62(RR-2):1-28. 3. Robertson CA, Greenberg DP, Hedrick J, Pichichero M, Decker MD, Saunders M. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine. Vaccine. 2016;34(44):5273-5278. 4. Sanofi Pasteur Inc. Data on file (Menactra vaccine clinical development overview), November 2012. MKT25824. 5. National Institutes of Health (NIH). Post-licensure safety surveillance study of Menactra vaccine when administered as a 2-dose schedule to children. Updated November 11, 2016. Accessed April 25, 2018. 6. Sanofi Pasteur Inc. Data on file (Menactra vaccine total doses distributed since 2005), December 31, 2017. MKT33197. 7. LA County Department of Public Health. Preventing common vaccine administration errors. Rx for Prevention. 2010;1(9):5-7.

Guides, Materials, & Brochures


Safety Data Sheet (SDS)

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.